{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ellipta&page=2", "query": { "intervention": "Ellipta", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ellipta&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-04T21:49:31.244Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07282886", "title": "VENTURI (VENTilation Using Respiratory Imaging)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI", "type": "DRUG" }, { "name": "Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2026-03-15", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-04T21:49:31.244Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT07282886" }, { "nct_id": "NCT03012061", "title": "Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "UMEC", "type": "DRUG" }, { "name": "Fluticasone Furoate", "type": "DRUG" }, { "name": "Albuterol/salbutamol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 425, "start_date": "2017-01-25", "completion_date": "2018-05-30", "has_results": true, "last_update_posted_date": "2020-10-28", "last_synced_at": "2026-09-04T21:49:31.244Z", "location_count": 19, "location_summary": "Tempe, Arizona • Rolling Hills Estates, California • Colorado Springs, Colorado + 15 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Topeka", "state": "Kansas" }, { "city": "Natchitoches", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03012061" }, { "nct_id": "NCT02105974", "title": "Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Furoate/Vilanterol", "type": "DRUG" }, { "name": "Vilanterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1621, "start_date": "2014-04-07", "completion_date": "2015-07-08", "has_results": true, "last_update_posted_date": "2018-01-24", "last_synced_at": "2026-09-04T21:49:31.244Z", "location_count": 17, "location_summary": "Riverside, California • Sunset, Louisiana • Saint Charles, Missouri + 14 more", "locations": [ { "city": "Riverside", "state": "California" }, { "city": "Sunset", "state": "Louisiana" }, { "city": "Saint Charles", "state": "Missouri" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Wilmington", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02105974" }, { "nct_id": "NCT02301975", "title": "An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler", "type": "DRUG" }, { "name": "Placebo inhalation powders via ELLIPTA inhaler", "type": "DRUG" }, { "name": "Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler", "type": "DRUG" }, { "name": "Placebo inhalation powder via ACCUHALER/DISKUS inhaler", "type": "DRUG" }, { "name": "Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1526, "start_date": "2015-03-01", "completion_date": "2016-11-25", "has_results": true, "last_update_posted_date": "2018-08-06", "last_synced_at": "2026-09-04T21:49:31.244Z", "location_count": 34, "location_summary": "Huntington Beach, California • Riverside, California • Rolling Hills Estates, California + 30 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Upland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02301975" }, { "nct_id": "NCT02730351", "title": "Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone furoate/ Vilanterol 100 mcg/25 mcg", "type": "DRUG" }, { "name": "Fluticasone propionate 250 mcg", "type": "DRUG" }, { "name": "Placebo via ELLIPTA inhaler", "type": "DRUG" }, { "name": "Placebo via DISKUS / ACCUHALER", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "12 Years to 50 Years" }, "enrollment_count": 75, "start_date": "2016-05-25", "completion_date": "2017-02-03", "has_results": true, "last_update_posted_date": "2019-07-16", "last_synced_at": "2026-09-04T21:49:31.244Z", "location_count": 13, "location_summary": "Huntington Beach, California • Los Angeles, California • San Diego, California + 9 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02730351" }, { "nct_id": "NCT03478683", "title": "A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "budesonide/formoterol", "type": "DRUG" }, { "name": "albuterol/salbutamol", "type": "DRUG" }, { "name": "FF/UMEC/VI", "type": "DRUG" }, { "name": "Placebo to match budesonide/formoterol", "type": "DRUG" }, { "name": "tiotropium", "type": "DRUG" }, { "name": "Placebo to match FF/UMEC/VI", "type": "DRUG" }, { "name": "placebo to match tiotropium", "type": "DRUG" }, { "name": "ELLIPTA", "type": "DEVICE" }, { "name": "MDI", "type": "DEVICE" }, { "name": "HandiHaler", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 729, "start_date": "2018-06-25", "completion_date": "2019-03-14", "has_results": true, "last_update_posted_date": "2020-10-28", "last_synced_at": "2026-09-04T21:49:31.244Z", "location_count": 40, "location_summary": "Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more", "locations": [ { "city": "Gold River", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Clearwater", "state": "Florida" }, { "city": "DeBary", "state": "Florida" }, { "city": "Edgewater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03478683" }, { "nct_id": "NCT05169424", "title": "A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Trelegy Ellipta", "type": "DEVICE" }, { "name": "Stiolto Respimat", "type": "DEVICE" }, { "name": "Tiotropium + Olodaterol (5/5 mcg)", "type": "DRUG" }, { "name": "Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 9117, "start_date": "2021-12-17", "completion_date": "2021-12-27", "has_results": true, "last_update_posted_date": "2023-10-19", "last_synced_at": "2026-09-04T21:49:31.244Z", "location_count": 1, "location_summary": "White Plains, New York", "locations": [ { "city": "White Plains", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05169424" }, { "nct_id": "NCT03478696", "title": "A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "budesonide/formoterol", "type": "DRUG" }, { "name": "albuterol/salbutamol", "type": "DRUG" }, { "name": "FF/UMEC/VI", "type": "DRUG" }, { "name": "Placebo to match budesonide/formoterol", "type": "DRUG" }, { "name": "tiotropium", "type": "DRUG" }, { "name": "Placebo to match FF/UMEC/VI", "type": "DRUG" }, { "name": "placebo to match tiotropium", "type": "DRUG" }, { "name": "ELLIPTA", "type": "DEVICE" }, { "name": "MDI", "type": "DEVICE" }, { "name": "HandiHaler", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 732, "start_date": "2018-06-25", "completion_date": "2019-03-18", "has_results": true, "last_update_posted_date": "2020-10-28", "last_synced_at": "2026-09-04T21:49:31.244Z", "location_count": 42, "location_summary": "Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Westminster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03478696" }, { "nct_id": "NCT02924688", "title": "A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "FF/UMEC/VI (100/31.25/25) mcg", "type": "DRUG" }, { "name": "FF/UMEC/VI (100/62.5/25) mcg", "type": "DRUG" }, { "name": "FF/UMEC/VI (200/31.25/25) mcg", "type": "DRUG" }, { "name": "FF/UMEC/VI (200/62.5/25) mcg", "type": "DRUG" }, { "name": "FF/VI (100/25) mcg", "type": "DRUG" }, { "name": "FF/VI (200/25) mcg", "type": "DRUG" }, { "name": "Fluticasone/salmeterol (FSC)", "type": "DRUG" }, { "name": "Albuterol/salbutamol", "type": "DRUG" }, { "name": "ELLIPTA DPI", "type": "DEVICE" }, { "name": "DISKUS DPI", "type": "DEVICE" }, { "name": "METERED-DOSE INHALER (MDI)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2436, "start_date": "2016-10-13", "completion_date": "2019-02-22", "has_results": true, "last_update_posted_date": "2021-03-26", "last_synced_at": "2026-09-04T21:49:31.244Z", "location_count": 99, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02924688" }, { "nct_id": "NCT03949842", "title": "Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists", "type": "DRUG" }, { "name": "Fluticasone furoate/umeclidinium/vilanterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 0, "start_date": "2019-06-27", "completion_date": "2022-11-30", "has_results": false, "last_update_posted_date": "2020-04-22", "last_synced_at": "2026-09-04T21:49:31.244Z", "location_count": 3, "location_summary": "Waterbury, Connecticut • Charlotte, North Carolina • Layton, Utah", "locations": [ { "city": "Waterbury", "state": "Connecticut" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Layton", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03949842" } ] }